News

Patricia Jakel, MN, RN, AOCN, emphasized that the bond oncology nurses have with patients with cancer necessitates honest and often difficult conversations.

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.

Adding antihistamines to atezolizumab led to a 46% OS rate and a 23% PFS rate in metastatic urothelial carcinoma.

Panitumumab plus ipilimumab and nivolumab signaled complete or partial response in 18 patients with KRAS/NRAS/BRAF wild-type MSS mCRC at the 12-week mark.

Jessie Desir, PhD, RN, AMB-BC, OCN, discussed the need for awareness about cancer subtypes and their prevalence in certain populations.

Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.

Real-world data show that older adults with lenalidomide-refractory MM have poor survival outcomes after 1 to 3 lines of therapy.

Clinical response rates were higher in patients with phlebotomy-dependent polycythemia vera who received rusfertide than in those who received placebo.

The FDA has granted PYX-201 fast track designation for treatment of recurrent or metastatic HNSCC after progression post-chemoimmunotherapy.

Staying up to date with data from trials and information from organizations dedicated to cancer research is crucial for oncology nurses and APPs.

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.

Oncology nurses and APPs play a key role in educating patients on BREAKWATER study findings and their impact on BRAF-mutant CRC treatment.

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

Patients who receive certain cancer treatments are at greater risk of secondary malignancies and must be educated accordingly.

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for developing cancer.

Preliminary findings suggest that OH2 monotherapy is safe, with promising responses observed when combined with HX008 in locally advanced or metastatic sarcoma.

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer.

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

The FDA granted petosemtamab plus pembrolizumab breakthrough therapy status for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Median time to sustained worsening of symptoms was 23.7 months with cilta-cel, compared with 18.9 months with SOC.

The FDA granted SIGX1094 fast track status as a treatment option for diffuse gastric cancer.

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.

AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.

Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.

The FDA has given RZ-001 fast track designation for HCC after demonstrating therapeutic activity in preclinical studies.